600479 千金药业
2026/06 - 中期
人民幣(K¥)
与去年同期
比较
2025/12
人民幣(K¥)
2024/12
人民幣(K¥)
2023/12
人民幣(K¥)
2022/12
人民幣(K¥)
营业总收入1,918,2995.52%3,628,8433,629,8043,798,4854,026,279
减:营业总成本1,706,6464.30%3,248,8793,317,4633,357,5463,614,655
    其中:营业成本965,2886.12%1,858,8331,946,3392,046,7292,289,865
               财务费用1,729-136.09%(17,583)(27,061)(44,101)(3,330)
               资产减值损失(27)-98.67%(4,068)(7,823)(2,571)(1,270)
公允价值变动收益(864)-162.95%2,408635(1,597)(1,297)
投资收益13,658-27.36%44,19115,58218,79820,947
    其中:对联营企业和合营企业的投资收益(3,944)-183.84%11,731(2,060)8,024(3,640)
营业利润234,12319.88%437,252332,111461,940444,247
利润总额232,59219.66%435,102335,308460,419445,813
减:所得税费用32,69260.76%59,43132,69965,40358,667
净利润199,90014.86%375,671302,609395,017387,146
减:非控股权益19,053-58.86%89,37871,85274,61184,637
股东净利润180,84641.59%286,293230,757320,406302,509

市场价值指针
每股收益 (元) *0.36721.98%0.6650.5580.7580.707
每股派息 (元) *0.180--0.3800.3600.3500.350
每股净资产 (元) *6.1406.61%6.1525.8075.5715.156
审计意见 #--标准无保留意见标准无保留意见标准无保留意见标准无保留意见
回页顶
备注: *未调整数据
#只提供简体内容